Gerresheimer consensus stays cautious, shares hover below recent highs

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-26, 10:29.

Gerresheimer (DE000A0LD6E6) opens the day with a mixed analyst picture. The MDAX-listed packaging specialist’s shares trade in the mid-20 euro range on Xetra, with consensus estimates pointing to limited upside according to recent data from German platforms.

What recent estimates show

On finanzen.net, Gerresheimer is tracked with a last price indication around 26.20 euros, slightly below the previous day, reflecting muted short-term momentum. The site shows a spread of analyst targets around this level, with several houses cautious on the valuation after a volatile first half.

MarketBeat’s coverage of the Xetra-listed Gerresheimer stock highlights a recent close at approximately 26.42 euros on June 25, 2026, with a market capitalization near 904 million euros and a price/earnings ratio around 7.9, underscoring the discounted earnings multiple versus broader healthcare peers. While MarketBeat does not aggregate a strong buy consensus, it notes the absence of a clear, unified rating profile, suggesting investors face a fragmented analyst view.

How analysts frame the stock

Several German and international research outlets have in recent months recalibrated their stance on Gerresheimer, citing the challenging environment for medical packaging and devices and the integration of past acquisitions. Earlier commentary on related healthcare names published by Yahoo Finance and finance portals indicated that smaller med-tech and packaging players can experience pronounced share price swings when guidance shifts or regulatory conditions tighten, a backdrop that informs the cautious tone on Gerresheimer as well.

Against this sector context, Gerresheimer stands alongside peers such as Geberit in the broader European health and industrial packaging space, even though it occupies a more specialized niche. The company’s relatively low P/E ratio compared with some large-cap healthcare and industrial peers underlines a perception of earnings risk, which is reflected in the restrained consensus targets.

The product behind Gerresheimer

Gerresheimer generates its revenue primarily from manufacturing medical and pharmaceutical packaging, drug delivery devices and related solutions for customers in Germany and internationally. Its portfolio includes glass and plastic primary packaging for liquids and solids, inhalers, and prefillable syringes, serving large pharmaceutical and biotech customers across Europe, North America and emerging markets.

Where the shares trade today

The Gerresheimer shares (DE000A0LD6E6) most recently traded on Xetra around 26.30 euros on June 26, 2026, in early indications, with Stuttgart quotations showing roughly 26.20 euros at 06:16 CET, underlining tight trading ranges in the German venues.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or any other form of financial guidance. All data are based on publicly available sources believed to be reliable at the time of writing, without guarantee for accuracy or completeness.